Navigation Links
Global Alzheimer Disease New Drugs, Markets and Companies 2017-2025: Alzheimer's Disease Remains a Challenge in Management - Research and Markets
Date:2/1/2017

DUBLIN, Feb. 1, 2017 /PRNewswire/ --

Research and Markets has announced the addition of Jain PharmaBiotech's new report "Alzheimer Disease - New Drugs, Markets and Companies" to their offering.

Alzheimer's disease remains a challenge in management. With nearly 8 million sufferers from this condition in the seven major markets of the world and anticipated increases in the future. Considerable research is in progress to understand the pathomechanism of the disease and find a cure. The only drugs approved currently are acetylcholinesterase inhibitors but they do not correct the basic pathology of the disease, beta amyloid deposits and neurofibrillary tangles. Several new approaches emphasize neuroprotection as well.

The current management of Alzheimer's disease is reviewed and it involves a multidisciplinary approach. Acetylcholinesterase inhibitors are mostly a symptomatic treatment but some claims are made about a neuroprotective effect. Currently the only approved neuroprotective therapy in is memantine. Management of these patients also require neuroleptics for aggressive behavior and antidepressants. There is an emphasis on early detection at the stage of mild cognitive impairment and early institution of neuroprotective measures. The value of mental exercise in delaying the onset of Alzheimer's disease is being recognized.

Research in Alzheimer's disease still aims at elucidating the basic pathomechanisms. Animal models are important for research, particularly in testing some of the potential therapeutic approaches. There is considerable research in progress at the various centers, some of which is funded by the National Institute of Aging of the National Institutes of Health.

Over 300 different compounds are at various stages of development for the treatment of Alzheimer's disease. These are classified and described. There are non-pharmacological approaches such as vagal nerve stimulation and cerebrospinal fluid shunting, which are in clinical trials. As of September 2016, the number of clinical trials of AD on US Government clinical trials web site was over 1900. Selected 231 clinical trials are listed, of which 163 are still in progress and 68 were discontinued for various reasons.

Alzheimer's disease market in the seven major markets is analyzed for the year 2015. Several new therapies are expected to be in the market and the shares of various types of approaches are estimated for the future up to the year 2025. As a background to the markets, pharmacoeconomic aspects of care of Alzheimer disease patients and patterns of practice are reviewed in the seven major markets.

Profiles of 144 companies involved in developing diagnostics and therapeutics for Alzheimer's disease are presented along with 93 collaborations. The bibliography contains over 910 publications that are cited in the report.The report is supplemented with 46 tables and 21 figures.

Key Topics Covered:

Executive Summary

1. Clinical Features, Epidemiology and Pathology

2. Diagnostic Procedures for Alzheimer Disease

3. Management of Alzheimer Disease

4. Research in Alzheimer Disease

5. Drug Discovery & Development for Alzheimer Disease

6. Markets & Finances of AD Care

7. Companies

8. References

For more information about this report visit http://www.researchandmarkets.com/research/9gxk26/alzheimer_disease

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-alzheimer-disease-new-drugs-markets-and-companies-2017-2025-alzheimers-disease-remains-a-challenge-in-management---research-and-markets-300400576.html


'/>"/>
SOURCE Research and Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Global Information Online Market Research Portal Provides Complimentary Sample Service for Customers to Preview Reports by Global Industry Analysts
2. Cumberland Pharmaceuticals To Present At The UBS Global Healthcare Conference In New York
3. The Rockley Group and Content Rules Ink Deal to Extend Global Reach
4. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
5. Amgen To Present At The UBS Global Life Sciences Conference
6. HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast
7. Nektar Therapeutics President and CEO, Howard W. Robin, To Present at the 2013 UBS Global Healthcare Conference in New York City
8. PENTAX Medical And Hitachi-Aloka Medical Continue Joint Innovation And Global Leadership In Endoscopic Ultrasound Systems
9. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
10. TRACE Releases 2012 Global Enforcement Report
11. Valeant Pharmaceuticals To Present At 34th Annual Goldman Sachs Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... Texas , June 8, 2017 /PRNewswire/ ... a leading developer and manufacturer of diagnostic ... announced today that Cressey & Company LP ... firm, has completed a growth-focused investment in ... a majority ownership position from selling shareholder, ...
(Date:6/5/2017)... The Cincinnati location of Diplomat Specialty ... has been awarded a Top Workplaces 2017 honor ... based on an employee survey administered by WorkplaceDynamics, LLC, a ... survey measures several aspects of workplace culture, including alignment, execution, ... ...
(Date:6/1/2017)... , June 1, 2017 Nutriceutical Holdings (NH), ... Recommended Solutions (VRS), and KD Pharma Group have decided ... Holdings by KD Pharma Group. KD Pharma Group will ... option to acquire the entire company. "We ... They are committed to growing the NH companies by ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... June 26, 2017 , ... KICKICO , a protocol built on ... to solve many catastrophic issues within funding campaigns. KICKICO developers are testing the platform, ... crowdfunding - the raising of funds through the power of many - has been ...
(Date:6/25/2017)... ... 2017 , ... An increase in wetter weather in the Northern California area ... that; a humdinger of an allergy season. A relief from drought conditions is most ... grass and weed pollen. , “Our patients have been reporting the typical allergy ...
(Date:6/24/2017)... ... June 24, 2017 , ... The Pennsylvania Athletic Trainers’ ... Bayfront and Erie Convention Center on June 8-10. The weekend consisted of ... bowl, award and scholarship presentations, and professional networking. , On Friday June ...
(Date:6/23/2017)... ... June 23, 2017 , ... "The ... will ultimately do significant harm to people with all chronic conditions, including mental ... it leaves in place the Affordable Care Act (ACA) requirement that insurers cover ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... surgeon practicing in Newburgh, New York, has recently begun offering three new minimally ... offering the best cutting-edge procedures and reducing downtime, Dr. Rubinstein is excited to ...
Breaking Medicine News(10 mins):